The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2017 | iFCG: a promising new regimen for treating IGHV-mutated CLL
Nitin Jain, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, talks to us about the potential of iFCG, a combination of ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab in the treatment of chronic lymphocytic leukemia (CLL) with mutated IGHV gene and non-del(17p), as evaluated in a Phase II clinical trial (NCT02629809). He notes the positive results obtained from the trial, namely an increase in MRD negativity in patients, and hopes that this will translate to a better progression-free survival in these patients in the future. This interview was filmed at the American Society of Oncology (ASCO) 2017 Annual Meeting in Chicago, IL.
